Memorial Sloan Kettering Cancer Center

Peter McKenney

Eric G Pamer

Silvia Caballero

Sohn Kim

Charlie Buffie

The present invention relates to methods and compositions for reducing the risk and severity ofinfection. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacterium, contributes substantially to resistance againstinfection. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids.

Methods and compositions for reducing clostridium difficile infection

The present disclosure relates to novel lantibiotics, lantibiotic pharmaceutical compositions, isolated and recombinant lantibiotic-producing bacteria, bacterial pharmaceutical compositions, methods of producing novel lantibiotics from lantibiotic-producing bacteria, and methods of using such lantibiotics, lantibiotic pharmaceutical compositions, and bacterial pharmaceutical compositions to treat gram-positive bacteria infections, including vancomycin resistant enterococci infections, in patients, and to treat food and other objects to avoid gram-positive bacteria contamination.

Lantibiotics, lantibiotic-producing bacteria, compositions and methods of production and use thereof

Methods and compositions for reducinginfection

The present invention relates to methods and compositions for reducing the risk and severity of vancomycin-resistantinfection or colonization. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteriaand/or the bacteriacontribute substantially to resistance against vancomycin-resistantinfection or colonization. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids in the case of

Methods and compositions for reducing vancomycin-resistant enterococci infection or colonization

The present invention relates to methods and compositions for reducing the risk and severity of vancomycin-resistant Enterococci infection or colonization. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteriaand/or the bacteriacontribute substantially to resistance against vancomycin-resistant Enterococci infection or colonization. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids in the case of

Growing community of inventors

New York, NY, United States of America

Peter McKenney